[HTML][HTML] Sarilumab plus standard of care vs standard of care for the treatment of severe COVID-19: a phase 3, randomized, open-labeled, multi-center study (ESCAPE …
I Mastrorosa, R Gagliardini, FV Segala, A Mondi… - …, 2023 - thelancet.com
Background Among interleukin-6 inhibitors suggested for use in COVID-19, there are few
robust evidences for the efficacy of sarilumab. Herein, we evaluated the efficacy and safety …
robust evidences for the efficacy of sarilumab. Herein, we evaluated the efficacy and safety …
A randomized placebo-controlled trial of sarilumab in hospitalized patients with Covid-19
S Sivapalasingam, DJ Lederer, R Bhore, N Hajizadeh… - MedRxiv, 2021 - medrxiv.org
ABSTRACT BACKGROUND Sarilumab (anti-interleukin-6 receptor-α monoclonal antibody)
may attenuate the inflammatory response in Covid-19. METHODS We performed an …
may attenuate the inflammatory response in Covid-19. METHODS We performed an …
[HTML][HTML] Subcutaneous IL-6 inhibitor sarilumab vs. Standard care in hospitalized patients with moderate-to-severe COVID-19: An open label randomized clinical trial
R García-Vicuña, SC Rodriguez-García… - Frontiers in …, 2022 - frontiersin.org
Background The use of IL-6 blockers in COVID-19 hospitalized patients has been
associated with a reduction in mortality compared to standard care. However, many …
associated with a reduction in mortality compared to standard care. However, many …
Early use of sarilumab in patients hospitalized with COVID-19 pneumonia and features of systemic inflammation: the SARICOR randomized clinical trial
N Merchante, S Cárcel, JC Garrido-Gracia… - Antimicrobial Agents …, 2022 - Am Soc Microbiol
The objective of this study was to investigate the efficacy and safety of early treatment with
sarilumab, added to standard of care (SOC), in hospitalized adults with COVID-19. Methods …
sarilumab, added to standard of care (SOC), in hospitalized adults with COVID-19. Methods …
Sarilumab treatment of hospitalised patients with severe or critical COVID-19: a multinational, randomised, adaptive, phase 3, double-blind, placebo-controlled trial
FX Lescure, H Honda, RA Fowler, JS Lazar, G Shi… - MedRxiv, 2021 - medrxiv.org
Background Elevated proinflammatory cytokines have been associated with 2019
coronavirus disease (COVID-19) severity. We assessed efficacy and safety of sarilumab, an …
coronavirus disease (COVID-19) severity. We assessed efficacy and safety of sarilumab, an …
Efficacy and safety of sarilumab in hospitalized patients with coronavirus disease 2019: a randomized clinical trial
S Sivapalasingam, DJ Lederer, R Bhore… - Clinical Infectious …, 2022 - academic.oup.com
Background Open-label platform trials and a prospective meta-analysis suggest efficacy of
anti–interleukin (IL)-6R therapies in hospitalized patients with coronavirus disease 2019 …
anti–interleukin (IL)-6R therapies in hospitalized patients with coronavirus disease 2019 …
Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial
FX Lescure, H Honda, RA Fowler, JS Lazar… - The Lancet …, 2021 - thelancet.com
Background Elevated proinflammatory cytokines are associated with greater COVID-19
severity. We aimed to assess safety and efficacy of sarilumab, an interleukin-6 receptor …
severity. We aimed to assess safety and efficacy of sarilumab, an interleukin-6 receptor …
Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial
Background Patients with COVID-19 pneumonia can have increased inflammation and
elevated cytokines, including interleukin (IL)-6, which might be deleterious. Thus, sarilumab …
elevated cytokines, including interleukin (IL)-6, which might be deleterious. Thus, sarilumab …
[HTML][HTML] Subcutaneous sarilumab for the treatment of hospitalized patients with moderate to severe COVID19 disease: a pragmatic, embedded randomized clinical …
W Branch-Elliman, R Ferguson, G Doros, P Woods… - PLoS …, 2022 - journals.plos.org
Importance and objective The aim of this pragmatic, embedded, adaptive trial was to
measure the effectiveness of the subcutaneous anti-IL-6R antibody sarilumab, when added …
measure the effectiveness of the subcutaneous anti-IL-6R antibody sarilumab, when added …
[HTML][HTML] Efficacy and safety of sarilumab in patients with COVID19 pneumonia: a randomized, phase III clinical trial (SARTRE study)
A Sancho-López, AF Caballero-Bermejo… - Infectious diseases and …, 2021 - Springer
Introduction SARS-CoV-2 pneumonia is often associated with hyper-inflammation. The
cytokine-storm-like is one of the targets of current therapies for coronavirus disease 2019 …
cytokine-storm-like is one of the targets of current therapies for coronavirus disease 2019 …